Biogen | BIIB - Pre Tax Profit


Biogen reported $-56M in Pre-Tax Profit for its fiscal quarter ending in December of 2025.





Pre Tax Profit Change Date
AbbVie USD 2.67B 1.71B Dec/2025
Acadia Pharmaceuticals USD 26.32M 18.28M Dec/2025
ALKERMES USD 100.74M 4.1M Sep/2025
Amgen USD 3.92B 2.35B Sep/2025
Bayer EUR -1.16B 735M Sep/2025
Biogen USD -56M 613.3M Dec/2025
BioMarin Pharmaceutical USD -26.32M 324.19M Sep/2025
Bristol-Myers Squibb USD 3.11B 1.34B Sep/2025
Eli Lilly USD 7.23B 456M Sep/2025
Esperion Therapeutics USD 63.67M 95M Dec/2025
Gilead Sciences USD 2.08B 1.56B Dec/2025
Incyte USD 389.94M 92.37M Dec/2025
Merck USD 6.74B 22M Sep/2025
Moderna USD -187M 631M Sep/2025
Neurocrine Biosciences USD 239.4M 52.4M Dec/2025
Novartis USD 4.64B 445M Dec/2025
Pfizer USD 3.33B 290M Sep/2025
PTC Therapeutics USD -139.08M 116.01M Dec/2025
Puma Biotechnology USD 20.61M 24.76M Sep/2024
Regeneron Pharmaceuticals USD 1.04B 719.6M Dec/2025
Sangamo BioSciences USD -36.05M 12.94M Jun/2024
Sanofi EUR -1.16B 5.5B Dec/2025
Sanofi EUR -1.16B 6.23B Dec/2025
Sarepta Therapeutics USD -407.67M 213.63M Dec/2025
Teva Pharmaceutical Industries USD 753M 662M Mar/2026
Ultragenyx Pharmaceutical USD -128M 51.54M Dec/2025
United Therapeutics USD 444M 6M Dec/2025
Vertex Pharmaceuticals USD 1.3B 15.8M Sep/2025